about
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerCancer biomarkers: the role of structured data reporting.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.A call to standardize preanalytic data elements for biospecimens.Analytic Validation of Immunohistochemistry Assays: New Benchmark Data From a Survey of 1085 Laboratories.Consensus statement on effective communication of urgent diagnoses and significant, unexpected diagnoses in surgical pathology and cytopathology from the College of American Pathologists and Association of Directors of Anatomic and Surgical PathologPrinciples of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center.Principles of Analytic Validation of Clinical Immunohistochemistry Assays.The Future of College of American Pathologists Cancer Protocols: Maintaining a Commitment to Patient Safety While Improving the User Experience.Analytic Validation of Immunohistochemical Assays: A Comparison of Laboratory Practices Before and After Introduction of an Evidence-Based Guideline.Stereotactic core-needle biopsy of the breast: a report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists.Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.Helicobacter pylori infection in pernicious anemia: a prospective controlled study.Progress in implementing HER2 testing guidelines.Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast.Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum.Recommendations for handling radioactive specimens obtained by sentinel lymphadenectomy. Surgical Pathology Committee of the College of American Pathologists, and the Association of Directors of Anatomic and Surgical Pathology.Prevalence of gastric metaplasia, inflammation, and Campylobacter pylori in the duodenum of members of a normal population.Primary mucosal malignant melanoma: an immunohistochemical study of 12 cases with comparison to cutaneous and metastatic melanomas.Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction.Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.Introducing new College of American Pathologists reporting templates for cancer biomarkers.The Lifecycle of an Evidence-Based Laboratory Practice Guideline: Origin, Update, Affirmation, and Impact!Core vs Breast Resection Specimen: Does It Make a Difference for HER2 Results?Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories.Flow cytometric DNA and nuclear antigen content in astrocytic neoplasms.Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateHistochemistry in the diagnosis of non-neoplastic gastrointestinal disordersHuman Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateAdenosquamous carcinoma of the lung: a clinical and pathologic study of seven casesConsensual interpretive guidelines for diagnostic immunohistochemistryWallenberg's syndrome caused by direct brainstem injuryClinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patientsIn replyIn Reply
P50
Q30494798-886980D6-62CE-40FA-A2D2-3450FA287D56Q30856980-14CD483F-CB4D-4FE1-8DC5-83F24BF0D42BQ33862786-33D4468F-02C0-4175-BD72-D6EF4FE2D808Q34928613-11AFA8BE-9A5C-4A14-B811-1C2A95516F2BQ36384772-F31F34CD-9E2F-41C5-B5AB-55DB479BDCEBQ37944930-08D91DB3-DDF7-44E7-9453-8ABDD78DBB4FQ38197280-2BC20A3F-D03B-4890-84F6-44EBD54F2723Q38603134-31FCE14C-822D-4805-8B23-810E0FE6C1B7Q38688167-D3D50C0A-6F03-4D78-921E-F490D3269740Q38756585-AEED69F4-7CBF-4405-AFCF-1D4D99496E83Q41470897-8FC6E7EA-AE05-4EF0-8CFD-8887E7398C77Q42669258-6E181CF8-82E9-4CFF-AC16-985B14B16B3AQ43683967-B5D929DF-8CDB-4A63-A8F2-6C870CB057A6Q43724380-775374F2-81C1-4F61-B6D2-9CD74828231DQ45952208-71C5FEAC-6D04-425D-8927-CD6EA2C06333Q46030526-CBDAEFDC-CAA4-4416-8ECF-C40DD2E3085BQ46076583-DD544A0A-ABDC-46D7-AAE5-63FF9AF06A0AQ46079331-EEA87261-B173-4296-8433-8C49F9C86DC3Q46093265-21205D8F-CAD7-4278-85B5-78903FFC6CFEQ46168298-4ED04AC4-DFBA-428E-BF21-5429BFDB5606Q46270367-A3444C71-915C-4B65-A94E-A543DA337796Q46877986-2D52C520-9F9C-424E-94EC-881435BF8FA7Q52643031-B5E125FF-766E-420C-9E98-D31E38B7A7F4Q54245567-F62F4910-CA3F-4050-98CE-2C7C314E64C4Q54462162-50A68BEE-8C24-40F5-B7EA-C19EB84F8EE1Q55486336-0DB03441-7E23-428F-9605-532F537B1D15Q57112562-347AB941-F4A3-4758-A5C2-3A39FFB768F8Q58121916-D7E4420C-FB58-43D5-AB86-BABFA4C802BEQ64018907-5F5634D8-014E-4977-996D-55050CC36CCAQ70088896-F4D6E14B-7134-4035-AA64-CC41739FB589Q74146892-C95C51C9-6230-4258-9934-B7EFB3C29328Q77371366-DABBC03A-9AB3-4293-8DDC-A19257B087E8Q84444670-F3DA00CF-AC68-4147-A16E-587AF385ABFEQ85712965-E7367F6C-FB38-4775-B85D-A1E214C260D0Q89375869-4D7F8E8D-E0F8-46EB-9046-10B6F3767960
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Patrick L. Fitzgibbons
@ast
Patrick L. Fitzgibbons
@en
Patrick L. Fitzgibbons
@es
Patrick L. Fitzgibbons
@nl
Patrick L. Fitzgibbons
@sl
type
label
Patrick L. Fitzgibbons
@ast
Patrick L. Fitzgibbons
@en
Patrick L. Fitzgibbons
@es
Patrick L. Fitzgibbons
@nl
Patrick L. Fitzgibbons
@sl
prefLabel
Patrick L. Fitzgibbons
@ast
Patrick L. Fitzgibbons
@en
Patrick L. Fitzgibbons
@es
Patrick L. Fitzgibbons
@nl
Patrick L. Fitzgibbons
@sl
P106
P1153
7004600606
P21
P31
P496
0000-0002-2998-6913